Dianthus Therapeutics ( NASDAQ ... TD Cowen 45th Annual Health Care Conference – Marino Garcia, Chief Executive Officer, will participate in a fireside chat on Wednesday, March 5 at 11:50 ...

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies.

Reports Q4 revenue $1.33M, consensus $859,700. “We remain on track to report top-line data in 2H’25 from our Phase 2 clinical trial of DNTH103 ...

March 11, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq ... along with improved safety and convenience could meaningfully advance the standard of care,” said Marino Garcia, Chief ...

NEW YORK and WALTHAM, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of ...

Reviewed by Mary Marlowe Leverette Fact checked by Sarah Scott Sweet William (Dianthus barbatus) is an herbaceous perennial or biennial that is often planted as an annual flower. It is a very ...

March 11, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics ... and convenience could meaningfully advance the standard of care,” said Marino Garcia, Chief Executive Officer of Dianthus ...

NEW YORK and WALTHAM, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody ...